Aptilon Corporation Doubles Revenue For the Six-Month 
Period Ended June 30, 2007

MONTREAL, August 28, 2007 - Aptilon Corporation (TSX.V: APZ) announced today its results for the three-month period ended June 30, 2007. Complete financial statements and MD&A are available on SEDAR at www.sedar.com. Revenues for the period were $2,102,184; an increase of 72% versus total revenue of $1,220,455 recognized in the three-month period ended June 30, 2006. Revenues for the six-month period ended June 30, 2007 increased 100% to $4,354,609 when compared to $2,180,577 revenue recognized in the six-month period ended June 30, 2006.

§         January 1 to June 30, 2007 revenues were $4,354,609 an increase of 100% compared to $2,180,577 for the same period in 2006.

§         For the three months ended June 30, 2007, revenues increased 72%, from $1,220,455 in 2006 to $2,102,184 in 2007.

§         Net loss amounted to $1,070,192 for the three months ended June 30, 2007, an increase of 112% over the net loss of $505,737 recorded for the same period in 2006

§         Working capital stood at $4.6 million at June 30, 2007.

§         Following the close of the quarter, Aptilon completed a public offering of common shares for aggregate gross proceeds of $10,000,000.

The net loss for the three-month period ended June 30, 2007 was $1,070,192 which represents a basic loss per share of $0.0077 (based on a weighted average number of common shares outstanding of 139,675,857 during the period. The current number of outstanding shares is 165,367,310.) The operating loss for the three-month period ended June 30, 2007 is attributed to additional financing for the growth of physician access, increased G&A expenses and the incremental commitment in direct sales and marketing efforts. G&A components contributing to the increase over the previous year, include $148,038 in stock-based compensation and $139,083 in foreign exchange loss. At June 30, 2007, the Company's working capital position was $4,607,891 compared to $5,783,848 at March 31, 2007 and $6,542,888 at December 31, 2006.

“We are pleased with results in the second quarter and by initial customer adoption of AxcelRx Live 5.0, Aptilon’s next generation bundle of web-based sales and marketing services featuring live sales representative-physician video detail sessions that was launched during the period” said Denis Martineau, President of Aptilon. Following the close of the quarter, on July 9, 2007, Aptilon announced the signing of an important enterprise commitment with Merck & Co. (“Merck”) that expands its contract for AxcelRx Live video detailing as a component of Merck’s alternative sales channel strategy.

Also, following the close of the quarter, on July 19, 2007, Aptilon completed a public offering of common shares pursuant to which the Company issued to investors 25,000,000 common shares at a price of $0.40 per common share, for aggregate gross proceeds of $10,000,000. “By significantly strengthening its available cash and working capital, Aptilon can now more rapidly expand the ReachNet recruiting network and thereby increase availability of sales and marketing interactions to interested, targeted physicians,” Martineau expanded.

About Aptilon

Aptilon enables pharmaceutical, biotech and medical device companies to effectively reach and interact with physicians via the Internet through its innovative AxcelRx Live video detailing (with company reps), virtual programs, e-Sampling, peer selling and other sales and marketing programs. Leading health care companies have adopted Aptilon’s “Sales Force of the Future” model, driving tens of thousands of high-quality rep-physician interactions averaging 8 to 10 minutes in length. Aptilon provides the infrastructure necessary for sales representatives to build physician awareness, understanding and preference during all stages of a products life cycle, from pre-launch education through end stage support. For more information, visit www.aptilon.com.

Forward-looking statements

This news release contains forward-looking information. These statements relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management of Aptilon. A number of factors could cause actual events, performance or results to differ materially from the events performance and results discussed in the forward-looking statements. These forward-looking statements are made as of the date hereof and Aptilon does not assume any obligation to update or revise them to reflect new events or circumstances.

###